

Lipoteichoic acid

Cat. No.:	HY-N9481
CAS No.:	56411-57-5
Target:	Complement System; Autophagy; mTOR; Akt; PI3K; ERK; Interleukin Related
Pathway:	Immunology/Inflammation; Autophagy; PI3K/Akt/mTOR; MAPK/ERK Pathway; Stem Cell/Wnt
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lipoteichoic acid

BIOLOGICAL ACTIVITY

Description	Lipoteichoic acid is an orally effect anti-inflammatory and antitumor agent. Lipoteichoic acid is a crucial immune molecule in Gram-positive bacteria that activates the complement system by inducing C3 and inhibiting CD55. Lipoteichoic acid regulates macrophage autophagy through the PI3K/Akt/mTOR pathway. Lipoteichoic acid induces lung damage in mice. Lipoteichoic acid inhibits the production of melanin ^{[1][2][3][4][5][6][7]} .																
In Vitro	Lipoteichoic acid (0.1-20 µg/mL; 12-48 h) induces macrophage autophagy by inhibiting PI3K/AKT/mTOR pathway^[2]. Lipoteichoic acid (0.1-100 µg/mL; 24 h) inhibits the production of melanin in B16F10 cells through MITF, ERK and PI3K/AKT signaling pathways^[3]. Lipoteichoic acid (50-100 ng/mL; 2-3 h) shows no cytotoxicity to HT-29 cells, decreases the secretion of TNF-α and increases the secretion of IL-10 in HT-29 cells treated with LPS (HY-D1056)^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis^[2] <table> <tr> <td>Cell Line:</td><td>macrophage</td></tr> <tr> <td>Concentration:</td><td>0.1, 1, 10, and 20 µg/mL</td></tr> <tr> <td>Incubation Time:</td><td>12, 24 and 48 h</td></tr> <tr> <td>Result:</td><td>Significantly decreased the expression levels of p-Akt and p-mTOR protein, but did not affect the expression of Akt and mTOR protein.</td></tr> </table> Western Blot Analysis^[3] <table> <tr> <td>Cell Line:</td><td>B16F10 cells</td></tr> <tr> <td>Concentration:</td><td>0.1, 1, 10 and 100 µg/mL</td></tr> <tr> <td>Incubation Time:</td><td>24 h</td></tr> <tr> <td>Result:</td><td>Reduced the level of MITF in a dose-dependent manner. Increased the phosphorylation levels of ERK, AKT and PI3K.</td></tr> </table>	Cell Line:	macrophage	Concentration:	0.1, 1, 10, and 20 µg/mL	Incubation Time:	12, 24 and 48 h	Result:	Significantly decreased the expression levels of p-Akt and p-mTOR protein, but did not affect the expression of Akt and mTOR protein.	Cell Line:	B16F10 cells	Concentration:	0.1, 1, 10 and 100 µg/mL	Incubation Time:	24 h	Result:	Reduced the level of MITF in a dose-dependent manner. Increased the phosphorylation levels of ERK, AKT and PI3K.
Cell Line:	macrophage																
Concentration:	0.1, 1, 10, and 20 µg/mL																
Incubation Time:	12, 24 and 48 h																
Result:	Significantly decreased the expression levels of p-Akt and p-mTOR protein, but did not affect the expression of Akt and mTOR protein.																
Cell Line:	B16F10 cells																
Concentration:	0.1, 1, 10 and 100 µg/mL																
Incubation Time:	24 h																
Result:	Reduced the level of MITF in a dose-dependent manner. Increased the phosphorylation levels of ERK, AKT and PI3K.																
In Vivo	Lipoteichoic acid (800 µg/100 µL; Oral gavage; 7 days) shows improvement in colitis mouse model^[4]. Lipoteichoic acid (0.1 mg; Oral administration; 20 days-34 weeks) has immunomodulatory and protective effects in UV-																

induced tumor models^[5].

Lipoteichoic acid (5 mg/kg; Intratracheal injection; Single dose) can induce lung injury in mice^[6].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DSS (HY-116282C) treated male swiss albino mice aged 6-8 weeks old ^[4]
Dosage:	800 µg/100 µL
Administration:	Oral gavage (i.g.); 7 days
Result:	Significantly improved external colitis symptoms, disease activity scores, and weight gain in colitis mice. Significantly improved key inflammatory markers such as the gut permeability, myeloperoxidase activity and histopathological damages in colon in colitis mice.
Animal Model:	Female Crl:SKH-1-hrBR hairless mice aged 8-12 weeks old (20-25 g) with UV-induced tumors ^[5]
Dosage:	100 µL (1 mg/mL)
Administration:	Oral administration; 20 days and 34 weeks (3 times a week)
Result:	Caused T cells in the mouse inguinal lymph nodes to produce higher levels of interferon-γ and a number of total, helper and cytotoxic T cells. Significantly delayed the appearance of tumors.
Animal Model:	Male C57BL/6 mice aged 6-8 weeks old (22±3 g) ^[6]
Dosage:	5 mg/kg
Administration:	Intratracheal injection; Single dose
Result:	Induced inflammatory cell infiltration, interalveolar septal thickening and alveolar collapse. Promoted the concentration of BALF total protein and the expression of inflammatory factors. Increased lung neutrophil infiltration and MPO activity.

REFERENCES

- [1]. Lin D, et al. Enterococcus faecalis lipoteichoic acid regulates macrophages autophagy via PI3K/Akt/mTOR pathway. Biochem Biophys Res Commun. 2018 Apr 15;498(4):1028-1036.
- [2]. Kim HR, et al. Lipoteichoic acid isolated from Lactobacillus plantarum inhibits melanogenesis in B16F10 mouse melanoma cells. Mol Cells. 2015;38(2):163-70.
- [3]. Weill FS, et al. Lipoteichoic acid from Lactobacillus rhamnosus GG as an oral photoprotective agent against UV-induced carcinogenesis. Br J Nutr. 2013 Feb 14;109(3):457-66.
- [4]. Pradhan D, et al. Postbiotic Lipoteichoic acid of probiotic Lactobacillus origin ameliorates inflammation in HT-29 cells and colitis mice. Int J Biol Macromol. 2023 May 1;236:123962.
- [5]. Zhang Y, et al Shikonin ameliorates lipoteichoic acid induced acute lung injury via promotion of neutrophil apoptosis. Mol Med Rep. 2021 Feb;23(2):133.
- [6]. Hara H, et al. The NLRP6 Inflammasome Recognizes Lipoteichoic Acid and Regulates Gram-Positive Pathogen Infection. Cell. 2018 Nov 29;175(6):1651-1664.e14.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA